News | April 25, 2025
We’re working at full force to put Bayer back on a profitable growth path: Bill Anderson, CEO, Bayer
Bayer expects 2025 to be the most difficult year of its turnaround
Bayer expects 2025 to be the most difficult year of its turnaround
YESAFILI, a vascular endothelial growth factor (VEGF) inhibitor, is used to treat several different types of ophthalmology conditions
The National IP Awards recognize outstanding contributions to India’s innovation economy through effective IP creation and commercialization
Sun Pharma has been involved in a patent infringement case with Incyte Corporation over LEQSELVI
PRX-PLUS has a unique product feature with its deep-impacting formula
This marks a significant milestone in Morepen’s strategic entry into one of the world’s largest pharmaceutical markets
The Formulation & Technology Centre intends to function as a technology storefront, offering advanced formulation and processing solutions to address the growing demand for complex drug formulations
Offers affordable, high-quality solutions for diabetes care
CDMO business delivered high-teen revenue growth for 9MFY25 driven by continued traction in the on-patent commercial manufacturing and generic API business
Novel illumination system with key components molded in Radel® PPSU for durability and repeated sterilization
Subscribe To Our Newsletter & Stay Updated
